Soft tissue sarcoma - historical
Revision as of 17:31, 12 February 2022 by Warner-admin (talk | contribs) (Text replacement - "|Randomized Phase II" to "|Randomized Phase 2")
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main soft tissue sarcoma page for current regimens.
2 regimens on this page
4 variants on this page
|
Locally advanced or metastatic disease, combination regimens
Doxorubicin & Olaratumab
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Tap et al. 2016 (CP15-0806) | 2010-2013 | Randomized Phase 2 (E-RT-esc) | Doxorubicin | Superior OS |
| Tap et al. 2020 (ANNOUNCE) | 2015-2018 | Phase 3 (E-esc) | Doxorubicin | Did not meet primary endpoint of OS |
Chemotherapy
- Doxorubicin (Adriamycin) as follows:
- Cycles 1 to 8: 75 mg/m2 IV once on day 1
Targeted therapy
- Olaratumab (Lartruvo) 15 mg/kg IV once per day on days 1 & 8
21-day cycles
Supportive medications
- CP15-0806, optional: Dexrazoxane (Zinecard) (dose not specified) IV once on day 1
References
- CP15-0806: Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. link to original article contains verified protocol link to PMC article PubMed NCT02451943